Cargando…

Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study

OBJECTIVE: This research aimed to explore the effects of probiotic administration on glycemic control and renal function in patients with diabetic nephropathy (DN). METHODS: The 101 participants were randomly divided into two treatment groups and 76 patients were included in the final analysis. In 7...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Hongyang, Zhang, Yan, Xu, Dongyan, Wang, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059722/
https://www.ncbi.nlm.nih.gov/pubmed/33666270
http://dx.doi.org/10.1002/jcla.23650
_version_ 1783681231707176960
author Jiang, Hongyang
Zhang, Yan
Xu, Dongyan
Wang, Qing
author_facet Jiang, Hongyang
Zhang, Yan
Xu, Dongyan
Wang, Qing
author_sort Jiang, Hongyang
collection PubMed
description OBJECTIVE: This research aimed to explore the effects of probiotic administration on glycemic control and renal function in patients with diabetic nephropathy (DN). METHODS: The 101 participants were randomly divided into two treatment groups and 76 patients were included in the final analysis. In 76 patients with diabetic nephropathy of type 2 diabetes, a randomized double‐blind and placebo‐controlled clinical trial was conducted to evaluate the administration of 3.2 × 10(9) CFU probiotic supplements per day (Bifidobacterium bifidum, 1.2 × 10(9) CFU, Lactobacillus acidophilus 4.2 × 10(9) CFU, Streptococcus thermophilus 4.3 × 10(9) CFU) for 12 weeks on glycemic control of patients, including fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin (HbA1c), microalbuminuria/creatinine (mAlb/Cr) and estimated glomerular filtration rate (eGFR) levels. The placebo group daily received empty capsules filled with starch. RESULTS: After 12 weeks, the administration of probiotics demonstrated a significant reduction in fasting blood glucose (10.68 ± 3.24 mmol/L before vs. 7.81 ± 2.77 mmol/L after, p < 0.05), HbA1c (8.19 ± 1.60% before vs. 7.32 ± 1.20% after, p < 0.05) and mAlb/Cr (101.60 ± 22.17 mg/g before vs. 67.53 ± 20.11 mg/g after, p < 0.05), while only mAlb/Cr level was significantly lower in the probiotic group than in the placebo group after intervention (67.53 ± 20.11 mg/g vs. 87.71 ± 23.01, p < 0.05). Meanwhile, there was no significant reduction of 2 h postprandial blood glucose level (18.95 ± 5.23 mmol/L vs. 17.35 ± 6.28 mmol/L, p = 0.24) and eGFR (84.34 ± 6.97 ml/min vs. 82.8 ± 8.72 ml/min, p = 0.45) in patients before and after probiotic intake. In addition, the placebo group failed to show any significant change of these parameters. CONCLUSION: This clinical study revealed probiotic administration could ameliorate glycemic control of patients with diabetic nephropathy, potentiating its therapeutic potential in clinical application.
format Online
Article
Text
id pubmed-8059722
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80597222021-04-23 Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study Jiang, Hongyang Zhang, Yan Xu, Dongyan Wang, Qing J Clin Lab Anal Research Articles OBJECTIVE: This research aimed to explore the effects of probiotic administration on glycemic control and renal function in patients with diabetic nephropathy (DN). METHODS: The 101 participants were randomly divided into two treatment groups and 76 patients were included in the final analysis. In 76 patients with diabetic nephropathy of type 2 diabetes, a randomized double‐blind and placebo‐controlled clinical trial was conducted to evaluate the administration of 3.2 × 10(9) CFU probiotic supplements per day (Bifidobacterium bifidum, 1.2 × 10(9) CFU, Lactobacillus acidophilus 4.2 × 10(9) CFU, Streptococcus thermophilus 4.3 × 10(9) CFU) for 12 weeks on glycemic control of patients, including fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin (HbA1c), microalbuminuria/creatinine (mAlb/Cr) and estimated glomerular filtration rate (eGFR) levels. The placebo group daily received empty capsules filled with starch. RESULTS: After 12 weeks, the administration of probiotics demonstrated a significant reduction in fasting blood glucose (10.68 ± 3.24 mmol/L before vs. 7.81 ± 2.77 mmol/L after, p < 0.05), HbA1c (8.19 ± 1.60% before vs. 7.32 ± 1.20% after, p < 0.05) and mAlb/Cr (101.60 ± 22.17 mg/g before vs. 67.53 ± 20.11 mg/g after, p < 0.05), while only mAlb/Cr level was significantly lower in the probiotic group than in the placebo group after intervention (67.53 ± 20.11 mg/g vs. 87.71 ± 23.01, p < 0.05). Meanwhile, there was no significant reduction of 2 h postprandial blood glucose level (18.95 ± 5.23 mmol/L vs. 17.35 ± 6.28 mmol/L, p = 0.24) and eGFR (84.34 ± 6.97 ml/min vs. 82.8 ± 8.72 ml/min, p = 0.45) in patients before and after probiotic intake. In addition, the placebo group failed to show any significant change of these parameters. CONCLUSION: This clinical study revealed probiotic administration could ameliorate glycemic control of patients with diabetic nephropathy, potentiating its therapeutic potential in clinical application. John Wiley and Sons Inc. 2021-03-05 /pmc/articles/PMC8059722/ /pubmed/33666270 http://dx.doi.org/10.1002/jcla.23650 Text en © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Jiang, Hongyang
Zhang, Yan
Xu, Dongyan
Wang, Qing
Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study
title Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study
title_full Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study
title_fullStr Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study
title_full_unstemmed Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study
title_short Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study
title_sort probiotics ameliorates glycemic control of patients with diabetic nephropathy: a randomized clinical study
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059722/
https://www.ncbi.nlm.nih.gov/pubmed/33666270
http://dx.doi.org/10.1002/jcla.23650
work_keys_str_mv AT jianghongyang probioticsamelioratesglycemiccontrolofpatientswithdiabeticnephropathyarandomizedclinicalstudy
AT zhangyan probioticsamelioratesglycemiccontrolofpatientswithdiabeticnephropathyarandomizedclinicalstudy
AT xudongyan probioticsamelioratesglycemiccontrolofpatientswithdiabeticnephropathyarandomizedclinicalstudy
AT wangqing probioticsamelioratesglycemiccontrolofpatientswithdiabeticnephropathyarandomizedclinicalstudy